Dacarbazine

Revision as of 19:31, 27 September 2011 by WikiBot (talk | contribs) (Protected "Dacarbazine": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)))
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Dacarbazine
File:Dacarbazine structure.png
Clinical data
Pregnancy
category
  • C
Routes of
administration
IV
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability?
Metabolism?
Elimination half-life5 hours
Excretion40% renal (unchanged)
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC6H10N6O
Molar mass182.18

WikiDoc Resources for Dacarbazine

Articles

Most recent articles on Dacarbazine

Most cited articles on Dacarbazine

Review articles on Dacarbazine

Articles on Dacarbazine in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Dacarbazine

Images of Dacarbazine

Photos of Dacarbazine

Podcasts & MP3s on Dacarbazine

Videos on Dacarbazine

Evidence Based Medicine

Cochrane Collaboration on Dacarbazine

Bandolier on Dacarbazine

TRIP on Dacarbazine

Clinical Trials

Ongoing Trials on Dacarbazine at Clinical Trials.gov

Trial results on Dacarbazine

Clinical Trials on Dacarbazine at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Dacarbazine

NICE Guidance on Dacarbazine

NHS PRODIGY Guidance

FDA on Dacarbazine

CDC on Dacarbazine

Books

Books on Dacarbazine

News

Dacarbazine in the news

Be alerted to news on Dacarbazine

News trends on Dacarbazine

Commentary

Blogs on Dacarbazine

Definitions

Definitions of Dacarbazine

Patient Resources / Community

Patient resources on Dacarbazine

Discussion groups on Dacarbazine

Patient Handouts on Dacarbazine

Directions to Hospitals Treating Dacarbazine

Risk calculators and risk factors for Dacarbazine

Healthcare Provider Resources

Symptoms of Dacarbazine

Causes & Risk Factors for Dacarbazine

Diagnostic studies for Dacarbazine

Treatment of Dacarbazine

Continuing Medical Education (CME)

CME Programs on Dacarbazine

International

Dacarbazine en Espanol

Dacarbazine en Francais

Business

Dacarbazine in the Marketplace

Patents on Dacarbazine

Experimental / Informatics

List of terms related to Dacarbazine

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Dacarbazine (da-KAR-ba-zeen) (brand names DTIC, DTIC-Dome; also known as DIC or Imidazole Carboxamide) is an antineoplastic chemotherapy drug used in the treatment of various cancers, among them malignant melanoma and Hodgkin lymphoma. Antineoplastic drugs are drugs which interfere with cell growth and impede the formation of new tissue - in this case, tumor tissue. These drugs are also known as cytotoxic drugs. Dacarbazine belongs to the family of chemicals known as alkylating agents. Dacarbazine is normally administered by injection (a shot) or intravenous infusion (IV) under the immediate supervision of a doctor or nurse.

History

Dacarbazine gained FDA approval in May 1975 as DTIC-Dome. The drug was initially marketed by Bayer.

Side effects

Like many chemotherapy drugs, dacarbazine may have numerous serious side effects, because it interferes with normal cell growth as well as cancer cell growth. Among the most serious possible side effects are birth defects to children conceived or carried during treatment; sterility, possibly permanent; or immune suppression (reduced ability to fight infection or disease). Like most powerful drugs, it may produce more common side effects like nausea, fatigue, headache, etc.

Common uses

As of mid-2006, dacarbazine is commonly used as a single agent in the treatment of metastatic melanoma, and as part of the ABVD chemotherapy regimen to treat Hodgkin lymphoma.

Experimental

Dacarbazine + Oblimersen. In clinical trials for malignant melanoma.

Suppliers

Bayer continues to supply DTIC-Dome. There are also generic versions of dacarbazine available from APP, Bedford, Mayne Pharma and Sicor (Teva).

See also

Sources

Template:SIB Template:WH Template:WikiDoc Sources